Tag Archive for: Collaboration

New Danish research centre to make designed proteins with vast potential

Designed proteins are anticipated to have groundbreaking impact on a range of issues from treating disease to tackling environmental problems. With a DKK 700 million grant from the Novo Nordisk Foundation and headed by Professor Dek Woolfson, a new Center for Protein Design (CPD) at the University of Copenhagen has ambitions to match this potential. […]

Sofinnova Partners collaborates with NVIDIA to accelerate European life sciences startups

Delivers high-performing AI infrastructure through NVIDIA DGX Cloud Lepton to portfolio companies, creating a powerful competitive advantage in $100B+ life sciences market BioCorteX, Bioptimus, Cure51, and Latent Labs among first cohort of startups to gain GPU capacity credits, helping position Europe at forefront of AI-driven drug discovery revolution PARIS, France – June, 11, 2025 – […]

Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology

License agreement centered around development of a single ADC program Usage of Synaffix GlycoConnect®, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagement Amsterdam, The Netherlands, 9 January 2025 — Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with […]

Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology

Amsterdam, The Netherlands, Basel, Switzerland and Ingelheim, Germany, (9 January 2025) — Boehringer Ingelheim and Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs), today announced that Boehringer has licensed Synaffix’s ADC technology. This new partnership significantly bolsters Boehringer’s ADC portfolio, driven […]

Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS

Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab’s antibody discovery platform. Cambridge, UK, 9 January 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a collaboration with Lilly to discover novel […]

© Optimum Strategic Communications.